F. Senecal

发表

Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer

G. Lyman, C. A. Blau, D. Veenstra, 2017, JCO precision oncology.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results

E. Perez, L. Denis, P. Mainwaring, 2005 .

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed

Thomas C. Chen, A. Schönthal, Thomas C Chen, 2022, Frontiers in Oncology.

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.

E. Stepanski, D. Henry, L. Schwartzberg, 2009, Breast.

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

L. Schwartzberg, D. Tomita, L. Yee, 2004, The oncologist.

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Mark D Anderson, Jennie W. Taylor, Mark D. Anderson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

J. George, J. Bussel, C. Kessler, 2008, The Lancet.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

H. Rugo, M. Gnant, H. Iwata, 2020, Clinical breast cancer.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, Lei Zhou, A. Stopeck, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Chris P. Miller, D. Haussler, Su-In Lee, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, A. Stopeck, C. Barrios, 2012 .

Effi cacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial

J. George, J. Bussel, C. Kessler, 2008 .

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

M. Dorschner, Janusz Dutkowski, B. Mecham, 2022, JCO precision oncology.

Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression

William Stafford Noble, W. L. Ruzzo, D. Haussler, 2016, bioRxiv.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

G. Demetri, P. LoRusso, L. Dirix, 2018, Investigational New Drugs.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

M. Buyse, L. Fallowfield, D. Cella, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.

N. Gabrail, L. Schwartzberg, D. Tomita, 2005, Clinical breast cancer.